With a commitment to advancing innovative technology to ensure people living with structural heart diseases have safe and effective treatment options, Abbott was the first to develop minimally invasive transcatheter edge-to-edge repair (TEER*) therapy for patients with mitral regurgitation (MR) and tricuspid regurgitation (TR), and reimagined the minimally invasive treatment of aortic stenosis.
*TEER is also referred to TMVr (Transcatheter Mitral Valve Repair)
MitraClip™ Transcatheter Edge-to-Edge Repair (TEER) procedure is a minimally invasive treatment option, uniquely designed for the mitral valve, for select patients with primary or secondary MR. As the first TEER therapy recommended by ACC/AHA1 and ESC/EACTS2-3 guidelines and by ASPC Recommendation,4 MitraClip is the only tailored therapy with over 18+ years of clinical experience and more than 150,000 patients treated worldwide,5 allowing physicians to treat more patients with more options.
Advancing the forefront of innovative design, the Navitor™ Transcatheter Aortic Valve Implantation (TAVI) System brings together smart PVL-sealing technology, exceptional single-digit gradients,6 stable deployment, accurate valve placement and uncompromised coronary access to achieve excellent clinical outcomes.
Portico™ with FlexNav™ Transcatheter Aortic Valve Implantation (TAVI) System offers patients with aortic stenosis a minimally invasive treatment option. The Portico™ valve is the first fully resheathable,* repositionable,* and retrievable* valve, while the FlexNav™ delivery system offers remarkable deliverability and exceptionally smooth tracking to treat every TAVI case.7-9
*Until fully deployed
Tendyne™ Transcatheter Mitral Valve Replacement (TMVR) System is first-in-class technology that offers select patients with MR who are at high risk for surgery, a minimally invasive option for mitral valve replacement. The Tendyne TMVR systems provide symptom relief and quality of life improvement by safely and effectively reducing MR.
TriClip™ Transcatheter Edge-to-Edge Repair (TEER) is a minimally invasive treatment option for patients with symptomatic severe Tricuspid Regurgitation (TR). TriClip TEER offers unmatched stability, precision, and control for the unique challenges of the tricuspid anatomy to achieve sustained, clinically significant improvements in the lives of TR patients.
MAT-2011954 v5.0
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0